| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tetraheptylammonium bromide does not have a defined biological target as a therapeutic agent. It is a quaternary ammonium salt used as a phase-transfer catalyst, electrolyte, and surfactant. The compound is not intended to exert pharmacological effects. Its utility lies in its chemical properties as a phase-transfer catalyst and surfactant.
|
|---|---|
| ln Vitro |
Tetraheptylammonium bromide is a biochemical reagent that can be utilized in studies pertaining to life sciences as an organic compound or biological material.
Specific in vitro activity data for Tetraheptylammonium bromide as a pharmacological agent are not documented in the literature, as it is primarily used as a research reagent and surfactant. The compound is not characterized for direct biological activities such as enzyme inhibition, receptor modulation, or antimicrobial effects. Its effects in biological systems, if any, would be related to its properties as a surfactant and potential membrane disruption. |
| ln Vivo |
Tetraheptylammonium bromide is not used for in vivo pharmacological activity assessment as a drug compound. Its primary applications are as a phase-transfer catalyst, electrolyte, and surfactant in research. The compound is not intended to be administered to animals for pharmacological or toxicological studies. Its use is limited to research and industrial applications.
|
| Enzyme Assay |
Tetraheptylammonium bromide is not used in enzyme/receptor binding assays as a test compound. Its primary applications are as a phase-transfer catalyst and surfactant. When used in research, it may be employed in studies of phase-transfer catalysis or as a surfactant in various chemical reactions. Standard chemical protocols are employed for its use.
|
| Cell Assay |
Tetraheptylammonium bromide is not used in cell-based assays as a test compound. Its primary applications are as a phase-transfer catalyst and research reagent. The compound is not characterized for direct cellular effects, cytotoxicity, or any pharmacological activity. Its potential toxicity is a concern in laboratory settings, but it is not evaluated for pharmacological effects.
|
| Animal Protocol |
Tetraheptylammonium bromide is not used in animal studies as a pharmacological agent. Its primary applications are as a phase-transfer catalyst and surfactant in research. The compound is not intended to be administered to animals for efficacy evaluations. Its use is limited to research and industrial applications.
|
| ADME/Pharmacokinetics |
Tetraheptylammonium bromide has a molecular weight of 490.69 g/mol and a molecular formula of C₂₈H₆₀BrN. It is a white to off-white crystalline solid. The compound is used as a phase-transfer catalyst, electrolyte, and surfactant. It is typically stored under standard laboratory conditions at room temperature, protected from moisture and light.
|
| Toxicity/Toxicokinetics |
Tetraheptylammonium bromide is intended for research use only and is not approved for human therapeutic applications. As a quaternary ammonium salt, comprehensive toxicological data are not extensively documented in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
Tetraheptylammonium bromide (CAS#: 4368-51-8) is a quaternary ammonium salt used as a phase-transfer catalyst, electrolyte, and surfactant in research applications. This compound is not a drug and has not undergone clinical trials.
|
| Molecular Formula |
C28H60BRN
|
|---|---|
| Molecular Weight |
490.70
|
| Exact Mass |
489.39
|
| CAS # |
4368-51-8
|
| PubChem CID |
78073
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
87-89 °C(lit.)
|
| LogP |
6.688
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
30
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Br-].[N+](C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
YQIVQBMEBZGFBY-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C28H60N.BrH/c1-5-9-13-17-21-25-29(26-22-18-14-10-6-2,27-23-19-15-11-7-3)28-24-20-16-12-8-4;/h5-28H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
tetraheptylazanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~203.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0379 mL | 10.1895 mL | 20.3791 mL | |
| 5 mM | 0.4076 mL | 2.0379 mL | 4.0758 mL | |
| 10 mM | 0.2038 mL | 1.0190 mL | 2.0379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
